M atrix metalloproteinase 8 (MMP-8, neutrophil collagenase) is a proinflammatory collagenase secreted mainly by neutrophils. The main substrate of MMP-8 is collagen type I. In inflammatory conditions, MMP-8 breaks down and remodels extracellular matrix to facilitate leukocyte transmigration into tissues. MMP-8 is a mediator of both acute and chronic inflammations, and it is a central contributor in various inflammatory disorders, such as periodontitis and rheumatoid arthritis.
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risk for incident coronary artery disease (CAD) events and death. Moreover, adding MMP-8 to the Framingham risk profile resulted in a significant improvement of clinical net reclassification for death. 6 Because MMP-8 is a collagenolytic enzyme involved in the breakdown of extracellular matrix, it may increase the vulnerability of atherosclerotic plaques and contribute to plaque rupture. Unstable atherosclerotic plaques display elevated concentrations of MMP-8. 7, 8 The origin of elevated serum and plasma MMP-8 in CVDs remains, however, unclear.
Genetic factors explain up to 40% of variation in the concentrations of systemic inflammatory biomarkers. 9 Therefore, serum MMP-8 concentrations might also have a significant genetic component. The aim of our study was to use genomewide data to identify genetic variants associated with serum MMP-8 levels. To our knowledge, this is the first genomewide association study (GWAS) on serum MMP-8. We also investigated the association of MMP-8-related variants with CVD and overall mortality. Genetic information may help to elucidate the mechanisms leading to elevated serum MMP-8 levels in CVDs.
Materials and Methods

Study Populations
An overview of the study populations is shown in a flow chart in Figure I in the Data Supplement. The studies were approved by the local Ethics Committees, and the participants gave a written informed consent.
Corogene
The Corogene study includes 5295 Finnish patients who were assigned to coronary angiography in the Helsinki University Central Hospital, Finland, between 2006 and 2008. 10 Blood samples were drawn from the arterial line during the coronary angiography into serum and citrate plasma vacuum tubes. The samples were handled according to the laboratory standards of the Helsinki University Central Hospital (accredited laboratory).
FINRISK
FINRISK is a Finnish national population-based study 11 that has been conducted in 5-year intervals since 1972. In the years 1992, 1997, 2002, and 2007 , the surveys were performed in 5 geographical areas in Finland, and they included a clinical examination, questionnaire, and laboratory analyses. Blood samples were collected during the health examination. Serum samples were taken without coagulation activators. The cases with prevalent coronary heart disease (CHD) or CVD at baseline were identified via (1) the questionnaire as a doctor-diagnosed disease, (2) the diseaseassociated drug reimbursement records from the Social Insurance Institution of Finland, including purchased medications and entitled reimbursements, and (3) the National Hospital Discharge register for hospitalizations. The study includes up to 20 years of follow-up data. The incident CHD events (acute myocardial infarction [AMI] , bypass surgery, and angioplasty), CVD events (CHD events and stroke), and all-cause deaths during the follow-up were identified via (1) the drug reimbursement records from the Social Insurance Institution of Finland, (2) the National Hospital Discharge register for hospitalizations, and (3) the National Causes-ofDeath Register.
In our study, the FINRISK 1997 cohort was used for the GWAS of serum MMP-8. The FINRISK cohorts 1992 (n=4294), 1997 (n=5796), 2002 (n=5974), and 2007 (n=4549) were used for examining associations between the GWAS top single nucleotide polymorphisms (SNPs) and prevalent and incident CVD events and all-cause mortality.
Measurement of Serum and Plasma MMP-8 Concentrations
MMP-8 was measured from serum samples of the Corogene and FINRISK 1997 subjects with a time-resolved immunofluorometric assay (Medix Biochemica, Kauniainen, Finland) according to the manufacturer's instructions.
To study the effect of GWAS top SNPs on plasma MMP-8, we randomly chose 100 individuals with each genotype of rs800292 (300 individuals in total) and another 100 individuals with each genotype of rs1560833 (300 individuals in total) matched for age, sex, and CAD status from the Corogene cohort. Their citrate plasma samples were analyzed for MMP-8 by the same assay as the serum samples.
Genotyping and Imputation
Of the Corogene cohort, 2500 subjects with either acute coronary syndrome or previous myocardial infarction were genotyped with the Illumina Human 610K genotyping chip (Illumina HumanHap 610-Quad SNP array, San Diego, CA) at the Wellcome Trust Sanger Institute (Hinxton, Cambridge, United Kingdom). FINRISK 1997 subjects used in the GWAS were genotyped with Illumina CoreExome array (Illumina, San Diego, CA). Individuals with a failed sex check, low genotyping frequency (<95%), excess heterozygosity, or excess relatedness (third-degree or closer relatives, estimated identity by descent >0.1) were excluded. SNPs with a low call rate (<95%), a low minor allele frequency (<1%), and those that deviated from Hardy-Weinberg equilibrium (P<10 -6 ) were filtered out. The Corogene data set was imputed with MACH 1.16 using HapMap 2 release 22 CEU reference population, and the FINRISK 1997 data set was imputed with IMPUTE v2 using 1000 Genomes Project as the reference panel. Imputed SNPs were filtered for high imputation quality (the imputation confidence score r 2 >0.8) and for minor allele frequency (>1%) resulting in ≈2.3 million autosomal SNPs for the Corogene subjects and ≈7.4 million autosomal SNPs for the FINRISK 1997 subjects.
In total, genotype data and serum MMP-8 concentrations were available for 2203 subjects of the Corogene cohort and 3846 subjects of the FINRISK 1997 cohort.
Other FINRISK cohorts were genotyped with Illumina HumanCoreExome, Illumina OmniExpress, Illumina Human 610-Quad, or Affymetrix Genome-Wide Human SNP 6.0 arrays. Genome-Wide Association Study on Serum MMP-8
Statistical Analyses
Serum MMP-8 GWAS The MMP-8 concentrations were log-transformed before analyses because they were not normally distributed. Associations between serum MMP-8 and genetic polymorphisms were analyzed with linear regression adjusted for age, sex, CAD status at the time of blood collection (in Corogene), a regional indicator based on the 5 geographical study areas (in FINRISK), and 10 first dimensions of the multidimensional scaling on the matrix of the identity-by-state to adjust for any residual population structure. For imputed SNPs, estimated allele dosages were used. The analyses were performed with the ProbABEL package, PLINK software, and R software package.
The Corogene and FINRISK 1997 cohorts were first analyzed separately. In addition, a fixed-effect meta-analysis based on effect size and SE was performed using METAL software package (release March 25, 2011, http://csg.sph. umich.edu//abecasis/Metal/). 12 The meta-analysis included genomic control correction and a test for heterogeneity (calculation of I 2 ) between the samples. Quantile-Quantile plots were generated to compare the distribution of observed associations to that expected under the null hypothesis.
A genetic score was used to assess the proportion of variance in serum MMP-8 concentrations explained by the genes. The score was calculated as a weighted sum of the risk alleles of the top SNPs from each genome-wide significant locus with weights proportional to the effect estimates obtained from the meta-analysis. The risk alleles were defined as those that were associated with increased MMP-8 concentrations. The SNPs used in the calculation of the genetic risk score were independent of each other.
Conditional regression analysis was performed by adjusting for the SNP with strongest association to identify independent genetic markers. Regional association plots were generated with LocusZoom 13 using hg19/1000 Genomes Nov 2014 EUR as the reference population.
Plasma MMP-8 and the Lead SNPs Identified From Serum MMP-8 GWAS
The associations between plasma MMP-8 concentrations (logtransformed) and the genotypes of rs800292 and rs1560833 were analyzed in subjects matched for age, sex, and CAD status by linear regression assuming an additive model for the minor allele.
MMP-8-Associated Variants and CVD
The association between the genotypes of rs1560833, rs800292, and rs1061170 and prevalent and incident CHD and CVD events, AMI, stroke, and all-cause mortality were analyzed separately in men and women in the FINRISK 1992 (n=4294), 1997 (n=5796), 2002 (n=5974), and 2007 (n=4549) populations by logistic regression adjusted for study cohort, baseline age, and the regional indicator based on the geographical study areas. Time to event analyses were performed by Cox regression adjusted for study cohort and the regional indicator. The time at risk was defined as the age at the time of the event, death, or end of follow-up. An additive effect for the minor allele of the SNPs was assumed in all models. The analyses were performed by IBM SPSS Statistics software (version 22.0).
Analysis of eQTLs
To study whether the top SNPs identified from the serum MMP-8 GWAS were associated with gene expression levels in whole blood, we searched for trans-and cis-expression quantitative trait loci (eQTLs) in the Blood eQTL Browser (http://www.genenetwork.nl/bloodeqtlbrowser/).
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Measurement of Complement Activation in Serum Samples
We randomly chose 100 individuals with each genotype of the GWAS top SNP rs800292 (300 individuals in total) matched for age, sex, and CAD status from the Corogene cohort. The activities of classical, alternative, and lectin pathways of complement were measured from serum samples with the WIESLAB Complement system enzyme immunoassays (EuroDiagnostica, Malmö, Sweden) according to the instructions of the manufacturer. The differences in complement activity levels (expressed as percentage of positive control) between the genotypes were analyzed by linear regression assuming an additive effect for the minor allele.
Functional Experiments With Human Neutrophils
We studied the release of MMP-8 from neutrophils in response to complement activation. Serum samples from 12 male individuals with each genotype of rs800292 (GG, AG, and AA, 36 individuals in total) matched for age and CAD status were randomly selected from the Corogene cohort to be used in the experiment.
Neutrophils were isolated from fresh blood of a healthy donor with Polymorphprep (Axis-Shield PoC, Oslo, Norway) according to the instructions of the manufacturer. Red blood cell lysis was achieved with erythrocyte lysis buffer (150 mmol/L NH 4 Cl, 10 mmol/L NaHCO 3 , 1 mmol/L EDTA, pH 7.7),and the cells were placed into Hanks' Balanced Salt Solution. The alternative pathway of complement was activated in the serum samples with 2 mg/mL inulin, and the samples were applied to the neutrophils (10 6 cells/experiment). Neutrophils were incubated with the sera at +37°C for 2 hours, the samples were centrifuged at low speed, and supernatants were collected. Each incubation was performed in 4 replicates. As controls, neutrophils were incubated with 50 ng/mL phorbol 12-myristate 13-acetate, with 2 mg/mL inulin without serum, and in the absence of inulin and serum. MMP-8 was measured from the supernatants and, to account for background MMP-8, from the original sera with Human Quantikine MMP-8 ELISA kits (R&D Systems, Minneapolis). The means of the 4 replicated measurements were used in the statistical analyses. The difference in MMP-8 release between the genotypes was analyzed with linear regression assuming an additive effect for the minor allele.
Results
The characteristics of study cohorts are presented in Table 1 . The subjects of the Corogene cohort had higher median serum MMP-8 concentrations than the FINRISK 1997 subjects. Genome-Wide Association Study on Serum MMP-8
GWAS of Serum MMP-8 Concentrations
The GWAS and meta-analysis revealed that a total of 499 SNPs in 2 genetic loci in chromosome 1 were associated with serum MMP-8 concentrations (P<5×10 Serum MMP-8 concentrations were significantly associated with polymorphisms in the gene of complement factor H (CFH) in 1q31.3 ( Figure 2A ; Table 2 ). The lead SNP in the meta-analysis, rs800292 (minor allele frequency 0.30 in our population), causes a nonsynonymous G>A substitution for log-transformed MMP-8; Table 2 ). Several other SNPs in this region (KCNT2-CFH-CFHR3-CFHR1-CFHR4-CFHR2-CFHR5) in chromosome 1 also showed significant associations with serum MMP-8. For example, the CFH variant rs1061170 (Tyr402His) was associated with serum MMP-8 (P=1.0×10 -19 ; Table 2 ). Some of the SNPs were in complete linkage disequilibrium with rs800292 ( Figure 2A ) while some seemed to be unlinked (r 2 <0.2; Figure 2A ; Table II in the Data  Supplement ) .
Six SNPs in the S100A9-S100A12-S100A8 genetic region in 1q21.3 were also significantly associated with serum MMP-8 ( Figure 2B ). The most significant SNP in this locus, rs1560833 (minor allele frequency 0.28 in our population), is located near the 3′ end of the S100 calcium-binding protein A9 (S100A9) gene. Table 2 ). The 6 SNPs in this locus were in complete linkage disequilibrium (r 2 >0.8) with each other. According to the Blood eQTL Browser (14) , rs1560833 is significantly associated with the expressions of S100A12 (Z score=−21.64; P=7.6×10 -104 ), S100A8 (Z score=−9.28; P=1.7×10 -20 ), and S100A9 (Z score=−6.53; P=6.7×10 -11 ) in whole blood. The genetic score based on the genotypes of rs800292 and rs1560833 explained 3.8% of variance in serum MMP-8 concentrations in FINRISK 1997 and 2.4% in Corogene (Table III in the Data Supplement).
Polymorphisms in the MMP8 gene itself or near it did not show any association with serum MMP-8 concentration.
To determine whether the discovered SNPs had an independent association with serum MMP-8, we performed a conditional analysis conditioned on the top SNP rs800292 in both Corogene and FINRISK 1997 populations. The results were combined by a meta-analysis (Table II in locus were not associated with serum MMP-8 at genome-wide significant level after conditioning on rs800292. However, the SNPs in the S100A9-S100A12-S100A8 genetic region remained significantly associated with serum MMP-8 (P≈10 -16 ). Thus, the 2 signals arising from CFH and from S100A9-S100A12-S100A8 loci were independent.
Association Between SNPs and Plasma MMP-8 Concentrations
To study the differences between serum and plasma, we analyzed whether the top SNPs from the 2 loci identified from the serum MMP-8 GWAS were associated with plasma MMP-8 concentrations. We randomly chose an equal number of individuals with each genotype of rs800292 (GG, AG, and AA, n=100 for each) and with each genotype of rs1560833 (GG, AG, and AA, n=100 for each) matched for age, sex, and CAD status from the Corogene cohort and analyzed their plasma samples for MMP-8. 
Effect of rs800292 (CFH Val62Ile) on Complement Activation
To evaluate the effect of rs800292 polymorphism on complement activation in serum, we measured the activities of the classical, alternative, and lectin pathways of complement from serum samples of 100 individuals with each genotype of rs800292 (GG, AG, and AA, n=300 in total; Figure 3 ). The individuals were matched for age, sex, and CAD status. The minor allele of rs800292 was significantly associated with stronger activation of the alternative pathway (P from linear regression=0.002; Figure 3) . No differences were seen in the activities of the classical or lectin pathways.
Effect of rs800292 (CFH Val62Ile) on the Release of MMP-8 From Neutrophils
In functional experiments with isolated human neutrophils, the minor allele A of rs800292 (Ile variant of CFH) was Associations between serum MMP-8 (log-transformed) and genetic polymorphisms were analyzed with linear regression adjusted for age, sex, CAD status (in Corogene), a regional factor based on the 5 geographical study areas (in FINRISK), and 10 first dimensions of the multidimensional scaling on the matrix of the identity-by-state. For imputed SNPs, estimated allele dosages were used. Allele coding is based on the forward strand. ASPM indicates abnormal spindle microtubule assembly; CAD, coronary artery disease; CFH, complement factor H; CFHR, complement factor H related; Chr, chromosome; GWAS, genome-wide association study; KCNT2, potassium channel sodium-activated subfamily T member 2; MAF, minor allele frequency; MMP-8, matrix metalloproteinase 8; S100A9, S100 calcium-binding protein A9; and SNP, single nucleotide polymorphism.
*Positions are given according to NCBI Homo sapiens Annotation Release 107. †Effect size β expressed as the change in log 10 MMP-8 per additional copy of minor allele. ‡In Corogene, rs482934 was used as a proxy for rs1061170 (r 2 =0.97, D′=1 in 1000genomes EUR population) as rs1061170 did not pass quality control. 
Association Between MMP-8-Associated SNPs and CVD
We also investigated the association of the SNPs rs800292 (CFH), rs1061170 (CFH), and rs1560833 (near S100A9) with prevalent and incident CHD, CVD, AMI, stroke, and mortality in FINRISK 1992 FINRISK , 1997 FINRISK , 2002 , and 2007 populations ( Table 3 ). The GWAS top SNP, rs800292, was not associated with any of the outcomes. In addition, rs1061170 did not show a statistically significant association with CHD, CVD, AMI, or stroke. In women, the minor allele of rs1061170 was inversely associated with time of death in Cox regression. 
Discussion
Elevated levels of serum MMP-8 have been associated with CVDs in numerous previous studies. 2-4 MMP-8 was associated especially with incident CAD and AMI in our recent large study with the FINRISK 1997 cohort. 6 We performed a GWAS on serum MMP-8 levels and found that genetic variation in the gene of CFH was strongly associated with serum MMP-8. Polymorphisms in S100A9-S100A12-S100A8 gene region were associated with both serum and plasma MMP-8. Rs1560833, located downstream of S100A9, was associated with prevalent and incident CVD events in men but not in women.
The most significant association with serum MMP-8 was observed in the CFH locus in chromosome 1. The SNP with the strongest association, rs800292, is located in the second exon of CFH and causes a Val62Ile substitution in the CFH protein. The Ile62 variant was associated with lower serum MMP-8 concentrations. CFH is an important inhibitory regulator of the alternative pathway of complement. It binds to C3b, preventing the formation and promoting the dissociation of the C3bBb (C3 convertase) complex. According to a previous study, the Ile62 variant of CFH (rs800292 minor allele) increases binding of CFH to C3b, 15 thereby leading to decreased complement activation. It has also been shown that carriers of rs800292 minor allele (Ile62 variant) have lower serum levels of C3a desArg, suggesting less complement activation compared with the carriers of the major allele (Val62 variant). 16 The attenuated complement activation associated with the Ile62 variant of CFH is likely to result in decreased neutrophil activation and degranulation and thereby decreased MMP-8 release from the cells during preparation of serum. Indeed, this hypothesis was confirmed in our functional experiments, where the carriage of the minor allele of rs800292 resulted in a smaller release of MMP-8 from neutrophils, showing that activation of the alternative pathway of complement regulates the amount of neutrophil-derived MMP-8.
According to our results, rs800292 (CFH Val62Ile variation) was not associated with MMP-8 concentration in plasma, probably because the anticoagulants used in the preparation of plasma inhibit complement activation. 17 The association between CFH and serum MMP-8, but not plasma MMP-8, is probably related to different sample preparation method. Similar results were found by Reiner et al, 16 who discovered that rs800292 was associated with serum myeloperoxidase levels but not with plasma myeloperoxidase, and by Schnabel et al, 18 who found that the common Asp42Gly variant of duffy antigen/chemokine receptor Results from the functional experiments with isolated human neutrophils. The alternative pathway of complement was activated from serum samples of rs800292 GG, GA, and AA carriers (n=12 for each, N total =36). Serum was applied to neutrophils, and the release of matrix metalloproteinase 8 (MMP-8) was measured. The experiments were performed in quadruplicate. P value was obtained by linear regression assuming an additive model for the minor allele A. Genome-Wide Association Study on Serum MMP-8 is associated with serum, but not plasma, concentrations of monocyte chemoattractant protein-1. According to previous studies, concentrations of MMP-8 in plasma tend to be lower than those in serum even though there is a significant correlation between MMP-8 levels in both sample types. 19 Our results suggest that the difference might be related to complement activation in serum and complement inhibition in plasma.
Previously, the Ile62 variant of CFH has been associated with a decreased risk for age-related macular degeneration. 20, 21 Other genetic polymorphisms in CFH have been associated with numerous diseases, such as atypical hemolytic uremic syndrome 22 and age-related macular degeneration. 21, 23, 24 However, there are no reports on the role of MMP-8 in these diseases. Some studies suggest that the CFH An additive model for the minor allele was assumed in all models. Allele probabilities were used for imputed SNPs. Logistic regression models were adjusted for age, study region, and FINRISK cohort. Cox regression models were adjusted for study region and FINRISK cohort. Age at the time of the event was used as the time scale in the Cox regression. AMI indicates acute myocardial infarction; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; OR, odds ratio; and SNP, single nucleotide polymorphism. Genome-Wide Association Study on Serum MMP-8
Tyr402His variant (rs1061170) is associated with the risk of CHD, stroke, myocardial infarction, or cardiovascular mortality [25] [26] [27] while no association was found in other reports. 28, 29 In our study, the carriers of rs1061170 minor allele had increased serum MMP-8 concentrations, but this variant was not associated with CVD, CHD, or stroke in the FINRISK cohorts. We did not find associations between rs800292 and CVD either. In addition to CFH, another locus in chromosome 1 was significantly associated with serum MMP-8 concentrations. This locus contains several S100A genes, including the calcium-binding proteins S100A8, S100A9, and S100A12. The minor allele of rs1560833, which is located downstream of S100A9, was associated with decreased serum MMP-8 and plasma MMP-8, suggesting that the sample preparation does not affect this association. S100A8 (calgranulin A, MRP-8), S100A9 (calgranulin B, MRP-14), and S100A12 (calgranulin C, EN-RAGE) are proinflammatory mediators expressed mainly by neutrophils. In the presence of calcium, S100A8 and S100A9 form a S100A8/S100A9 complex known as calprotectin. S100A8, S100A9, S100A8/A9, and S100A12 can induce neutrophil recruitment, chemotaxis, and adhesion. [30] [31] [32] [33] Moreover, at least S100A9 stimulates neutrophil degranulation. 34 According to eQTL results, the minor allele of rs1560833 has a negative association with the expressions of S100A8, S100A9, and S100A12. Lower expression of these proteins may be associated with reduced activation and degranulation of neutrophils, leading to lower MMP-8 concentrations in blood.
As the central role of inflammation in the pathogenesis of atherosclerosis is established, S100A8, S100A9, and S100A12 proteins as indicators of inflammation in CVD have raised wide interest in previous studies. S100A8/A9 is expressed by neutrophils and macrophages in atherosclerotic lesions, and it is regarded as a marker of plaque instability. 35, 36 S100A12 is also associated with symptomatic plaques. 37 Elevated serum concentration of S100A8/A9 is associated with acute coronary syndrome and AMI, 38, 39 as well as with the risk of a first cardiovascular event in the general population, and a recurrent cardiovascular event in patients with acute coronary syndrome independently of traditional risk factors. [40] [41] [42] Moreover, it has been reported that plasma levels of S100A12 are associated with the risk of CHD. 43 These studies suggest that S100 proteins may have value as biomarkers of CVD. According to our results, rs1560833 (near S100A9) was significantly, although weakly, associated with prevalent and incident CVD events in men but not in women. The minor allele was associated with a lower risk. Because the association was relatively weak and seen only in men, replication in other populations is needed to verify the result. It remains to be determined whether genetic variation of S100A9-S100A12-S100A8 is related to CVD via MMP-8 or whether both S100A8/A9/ A12 proteins and MMP-8 reflect inflammatory processes contributing to CVDs.
The strengths of this study include 2 relatively large and independent study populations with different study designs and a long and complete follow-up of the FINRISK cohorts. The associations discovered by GWAS were strong, and they have a functional and biological basis. However, some limitations need to be acknowledged as well. Many of the studied SNPs showed significant heterogeneity between the study cohorts, which may be because of the fact that the Corogene subjects were cardiac patients assigned for coronary angiography, and their MMP-8 levels were higher compared with the general population represented by FINRISK 1997. MMP-8 concentrations were measured with the same assay in both cohorts, and therefore the variation is unlikely to result from a measurement bias. Unfortunately, we did not have S100A8, S100A9, or S100A12 concentrations available from our study populations. Although our study cohorts are independent, both are Finnish representing a middle-aged or older white population. It remains unclear why the association between rs1560833 and CVD was seen only in men.
To summarize, the results from our genetic and functional studies indicate that the complement system, especially its alternative pathway, regulates the amount of MMP-8 released from neutrophils. Moreover, S100A8, S100A9, and S100A12 proteins seem to influence the levels of circulating MMP-8, possibly via neutrophil activation and enhanced degranulation. Polymorphism in the S100A9-S100A12-S100A8 gene region showed a suggestive association with the risk for CVDs in men. Our results show that genetic variation determines a significant portion of circulating MMP-8 concentrations.
